1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Terns’ Early Data May Position It Well In GLP-1 Obesity Race

 
• By Joseph Haas

In a multiple-ascending dose Phase I trial, Terns’ oral GLP-1 agonist showed 4.9% placebo-adjusted weight loss at 28 weeks, with no severe gastrointestinal side effects.

obesity medication with tape measure
Terns looks competitive in the obesity GLP-1 agonist competition with Phase I data • Source: Shutterstock

The obesity space may have another serious entry as Terns Pharmaceuticals, Inc. unveiled Phase I data for its oral, daily GLP-1 agonist TERN-601 on 9 September that indicate competitive weight-loss performance at 28 days with a clean safety and tolerability profile. Terns is working to move TERN-601 quickly into Phase II in 2025.

Key Takeaways

  • Terns reported 4.9% placebo-adjusted weight loss at 28 weeks in a Phase I study of oral GLP-1 agonist TERN-601.

In a single and multiple-ascending dose trial design, Terns reported an absolute 5.5% reduction in weight from baseline with the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

 
• By Mandy Jackson

MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.

Ionis Targets Ultra-Rare Disease Market With Zilganersen

 
• By Alaric DeArment

The biotech announced positive topline results from its pivotal study in Alexander disease, which has an estimated population of about 300 in the US.

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

More from R&D

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

QL Biopharm’s Zovaglutide Offers Potentially Safer Once-Monthly Obesity Option

 
• By Dexter Jie Yan

Zovaglutide tied Amgen’s MariTide in weight reduction at Week 24 in a Phase II study, but with a potentially better safety profile. However, efficacy versus existing once-weekly drugs is a remaining question.